Mutations in GIGYF2 have recently been described as causative of Parkinson's disease in Europeans. In an attempt to replicate these results in independent populations, we sequenced the entire coding region of GIGYF2 in a large series of Portuguese and North American samples. We report the finding of two of the previously published mutations in neurologically normal Control individuals. This suggests that mutations in GIGYF2 are not strongly related to the development of the disease in either of these populations.
INTRODUCTION
Parkinson's disease [PD (MIM 168600)], the second most common form of neurodegeneration, is characterized by loss of dopaminergic neurons in the nigro-striatal pathway, leading to bradykinesia, resting tremor, muscular rigidity and postural instability (1) .
The genetic factors underlying PD have been sought with considerable success in the past decade. Thus far, family-based studies, whole-genome linkage scans and candidate-gene analyses have yielded 14 chromosomal loci (PARK1 -PARK14) in which mutations in seven genes are unequivocally linked to rare forms of PD (SNCA, PARK1 OMIM #168601 and PARK4, PRKN, PARK2 OMIM #602544; PINK1, PARK6 OMIM #605909; DJ-1, PARK7 OMIM #606324; LRRK2, ATP13A2, PARK9 OMIM #610513 and PLA2G6, PARK14 OMIM #603604) (2 -8) . Although the mechanism through which mutations in these genes exert their pathogenicity is not fully understood, SNCA and LRRK2 are known to cause autosomal-dominant disease, while the remaining cause autosomal-recessive PD. More controversial results have been obtained for loci such as PARK5 (9) and PARK13 (10, 11) .
PARK11 is located in chromosome 2q36-37 and was initially described by a whole-genome linkage analysis in a population of familial PD patients (12 -14) . Although conflicting results followed shortly (15) , it was also detected in an earlier association analysis (16) . The PARK11 locus spans 18cM encompassing 73 candidate genes (12 -14) where the highest LOD score was obtained for the marker D2S206, located within intron 21 of GIGYF2, a gene encoding a 1320 amino acid protein (Grb10-Interacting GYF Protein 2, gigyf2).
Because of this and because gigyf2 has been shown to interact with grb10 and consequently have a potential role in insulin and insulin-like growth factor signaling (17), Lautier et al. (18) recently performed a screening of pathogenic mutations in GIGYF2 in a series of 249 familial PD Cases and 237 Controls from two different populations in Europe. The authors reported 10 different mutations spread in an even manner throughout the gene in PD patients but not in Controls, suggesting that these variants would be the cause of the disease in these patients.
These results prompted us to undertake a complete screening of GIGYF2 mutations in a large series of 724 Cases and 911 neurologically normal Controls from two different populations.
RESULTS

Portuguese series
The Portuguese cohort yielded 31 variants (Table 2) , of these, seven were known polymorphisms present in dbSNP. Four non-synonymous variants were found only in Cases, while 16 non-synonymous variants were present only in Controls (Table 2) . Of the remaining 24 variants not present in dbSNP, six were synonymous changes, suggesting no functional change for the protein. None of the variants present in both Cases and Controls showed association with disease. Although the variants rs12328151 and rs2289912 showed a P-value ,0.05 after x 2 , they failed to maintain the association after Bonferroni correction (P . 0.7).
Interestingly, one of the variants present only in the Control group (p.N478T) had previously been reported as a pathogenic mutation (18) . In addition, the exon 29 p.L1230_Q1237del, which had also been suggested to be disease-causing, is present in this population with an increased frequency in the Control group.
We failed to find any of the remaining 8 variants previously associated with disease in our cohort.
US series
The US series harbored 40 different variants (Table 3 ) including seven described SNPs in exons 15, 16, 26, 29 and 31; and introns 3 and 28. None of these polymorphisms showed association with PD after x 2 test of association. Although rs2305138 showed a P-value of 0.04, this is not considered significant after multiple-test correction.
Interestingly, two of the variants Lautier et al. described as mutations in their series were found in this cohort in both Cases and Controls. These variants (c.3689-3712del24 and p.H1192R) were not associated with PD in our cohort after x 2 test for association (P ¼ 0.385 and 0.1621, respectively). In addition, we have found 26 novel variants of which 16 were non-synonymous. Of these, three (p.G108R, p.L1230_Q1236del and p.P1231_Q1232insQQ) were found in both Cases and Controls but were not associated with disease (P ¼ 0.58, 0.90 and 0.29, respectively). The remaining variants were found in either a single Control sample (p.S395T, p.R982Q, p.S1269G and p.Q1272E) or a single PD Case (p.D453G, p.M586T, p.Q599K, p.S729G, p.R778G, p.R895G, p.S1056C, p.N1270D and p.I1314V) ( Table 3) .
Except for p.A995A and p.K1015K which were found in homozygous state in a single Control sample, the rest of silent changes were found in heterozygous state in only one sample.
DISCUSSION
We present herein a detailed analysis of the genetic variability in the GIGYF2 gene and its association with PD in two large sets of Cases and age-matched Controls, from two geographically distinct populations. The sample originating from Portugal comprised a total of 267 PD samples and 451 healthy age-matched Controls, while the US series comprised 460 Cases and 460 Controls. A significant difference for the previously published study on GIGYF2 variants and PD is the fact that we used a different transcript-isoform 'a' (NM_001103147.1)-whereas the transcript studied before was isoform 'b' (NM_015575.3), which lacks one exon when compared with the former. Due to this difference, the present mutation numbering differs from the work previously published.
The combined analysis of both cohorts yielded 46 variants of which seven are SNPs already present in dbSNP. Most of the remaining variants were present in both Case and Control groups and, additionally, none was shown to be statistically associated with PD. Lautier et al. presented a list of 10 mutations that their results suggested to be pathogenic, and an additional mutation present in one Control individual. Although we failed to find all these mutations in our combined series, we did find three of them: p.L1230_Q1237del (described as Del LPQQQQQQ 1209 -1216 by Lautier et al.), p.N478T (first described as Asn457Thr) and p.H1992R
(described as His1171Arg). Although p.L1230_Q1237del was found in a similar number of Cases and Controls in both populations (P ¼ 0.37 and 0.84 in the Portuguese and US series respectively), p.N487T was only found in one Portuguese Control sample, and p.H1192R, identified by Lautier et al. in one Control individual only; it was present in both Cases and Controls in our US series, suggesting it to be a benign variant (Fig. 1) .
Interestingly we have found 37 new single nucleotide variants in our cohorts of which 26 are non-synonymous, and five deletion or insertion mutations in both PD and Control groups (Tables 2 and 3) ; this high number is probably reflective of the repeat rich nature of exons 26 and 29.
In order to test if there was an enrichment of rare non-synonymous mutations in Cases when compared with Controls, we compared the collective frequency of nonsynonymous alterations that were identified only in Cases, with the collective frequency of non-synonymous changes found only in Controls; a 2 Â 2 Fischer exact test of association showed no statistically significant difference (Table 4) .
In comparison with the report of Lautier et al., some differences should be noted. The first is the ethnicity of the cohorts studied. Although Lautier et al. screened samples originating in Italy and France, our study included samples from Portugal and the United States. It is possible, although we believe unlikely, that differences in the genetic background between these cohorts, result in disparities in the pathogenicity of the variants. A second difference to the previous study is the sample selection criteria. Although Lautier et al. selected samples with positive family history, we included samples with and without family history representative of PD of their respective populations. Although the number of samples with family history may be smaller in our combined cohort, 
the effect of pathogenic mutations in GIGYF2 in these samples would be evident. Another possibility is that the healthy individuals harboring mutations may in future convert to disease; the fact that we used age-matched Controls and that there is no enrichment of these mutations in the Case group support our supposition that this is also unlikely.
The literature is clearly scarce in results relating genetic variability of GIGYF2 with PD. We present the first follow-up study to the results published by Lautier et al. Although we cannot rule out a small genetic contribution of GIGYF2 to PD, our data seem to point in the direction that the pathogenic variants previously published are rare polymorphisms. We support this statement based on the fact that two of such mutations were found in our Control groups and that SNPs across GIGYF2 did not show any association with PD; we cannot of course unequivocally rule out the other previously identified mutations from having a role in disease.
The previous study used a rather small Control group to verify the presence of the variants (n ¼ 227), and thus rare variants may have been missed. We believe this is a critical and important finding; this gene has already been assigned a PARK designation (http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607688) and we feel, given the evidence that we present here, that such a designation may be premature or misleading.
MATERIALS AND METHODS
Portuguese series
The series originating from Portugal comprised 267 PD patients and 451 healthy Controls, their characteristics are presented in Table 1 . Patients were selected in a consecutive manner, in the Movement Disorder clinic of the University of Coimbra Hospital. Diagnosis followed the UK Brain Bank criteria (19) . Control samples were collected from healthy unrelated individuals from the same population and geographical regions. All Controls were subjected to a neurological examination and found free of any symptoms suggestive of parkinsonism.
US series
The US series were taken directly from pre-compiled panels from the National Institute of Neurological Disorders and Stroke (NINDS) funded Neurogenetics repository hosted by the Coriell Institute for research (NJ, USA). All participants provided written informed consent.
Neurologically normal Controls were derived from five different panels of DNA: NDPT002, NDPT006, NDPT009, NDPT022 and NDPT024, containing DNA from total of 460 unrelated individuals from North America, including 225 males and 235 females. All individuals were Caucasian and Human
lacked history of Alzheimer's disease, amyotrophic lateral sclerosis, ataxia, autism, bipolar disorder, brain aneurism, dementia, dystonia, or PD. None had any first-degree relative with a known primary neurological disorder and the mean age of participants was 68.57 (range 55-95). PD Cases were taken from five panels of DNA: NDPT001, NDPT005, NDPT007, NDPT017 and NDPT018. These panels contain DNA from 460 unrelated Caucasian individuals from North America with PD, including 258 males and 202 females. The mean age at onset is 66.36 years (range 50 -87) and they all showed at least one of the main clinical signs of PD such as resting tremor, rigidity, bradykinesia, gait disorder and postural instability at the disease onset. All subjects were questioned regarding family history of parkinsonism, dementia, tremor, gait disorders and other neurological dysfunction. Subjects both with and without a reported family history of PD were included. None were included who had three or more relatives with parkinsonism, nor with clear Mendelian inheritance of PD.
A more detailed description of both Case and Control samples, can be found at http://ccr.coriell.org/Sections/Collections/NINDS/DNAPanels.aspx?PgId=195&coll=ND
Sequencing analysis
Screening of GIGYF2 was carried out using genomic DNA of a total of 724 Cases and 911 neurologically normal Controls from two different populations. Polymerase chain reaction (PCR) amplification was performed in a final volume of 16 ml containing 10 ng of genomic DNA, 10 pmol of forward and reverse primers (sequence available upon request) and 12 ml of FastStart PCR Master mix (Roche). Primers for all coding exons and intron/exon boundaries were designed using ExonPrimer (http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html) for Each purified product was sequenced using Applied Biosystems BigDye terminator v3.1 sequencing chemistry as per manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The resulting reactions were purified and resolved on an ABI3730XL genetic analyzer (Applied Biosystems) and analyzed with Sequencher software v4.1.4 (Gene Codes Corporation, VA, USA).
Statistical analysis
Statistical analyses included Hardy -Weinberg equilibrium, x 2 and Bonferroni correction tests and were performed using PLINK v1.03 (20) . 
